1-7 of 7
Ashwin Gollerkeri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Aditi Shastri, Eric J Feldman, Alexander N Starodub, Tatyana Feldman, Cristina P Rodriguez, Zachary D. Epstein-Peterson, Don A. Stevens, Adam J Olszewski, Auris O Huen, Pierluigi Porcu, John C Reneau, Stefan K. Barta, Enrica Marchi, Ahmad H Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Sean Donohue, Joyoti Dey, Sagar Agarwal, Rahul Karnik, Ashwin Gollerkeri, Jared Gollob, Stephen D Smith
Journal: Blood
Blood (2023) 142 (Supplement 1): 3081.
https://doi.org/10.1182/blood-2023-181130
Published: 2023
Journal Articles

Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader

Ellie Ivanova, Cosmin A Tegla, Ekaterina Novikova, Alberto M Herrera, Briana Mullins, Jo-Ann Latkowski, Kenneth B. Hymes, Joyoti Dey, Bin Yang, Ashwin Gollerkeri, Jared Gollob, Sergei B. Koralov
Journal: Blood
Blood (2022) 140 (Supplement 1): 3557–3558.
https://doi.org/10.1182/blood-2022-156816
Published: 2022
Journal Articles

A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

Phillip CC Liu, Vaishali Dixit, Michele Mayo, Joyoti Dey, Karen Yuan, Rahul Karnik, Dirk Walther, Yatao Shi, Kirti Sharma, Haojing Rong, Bin Yang, Ashwin Gollerkeri, Jared Gollob, Chris DeSavi
Journal: Blood
Blood (2021) 138 (Supplement 1): 1865.
https://doi.org/10.1182/blood-2021-151125
Published: 2021
Journal Articles

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

Clinical Trials & Observations
Oliver Ottmann, Hervé Dombret, Giovanni Martinelli, Bengt Simonsson, Francois Guilhot, Richard A. Larson, Giovanna Rege-Cambrin, Jerald Radich, Andreas Hochhaus, Anne Marie Apanovitch, Ashwin Gollerkeri, Steven Coutre
Journal: Blood
Blood (2007) 110 (7): 2309–2315.
https://doi.org/10.1182/blood-2007-02-073528
Published: 2007
Journal Articles

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

Clinical Trials & Observations
Francois Guilhot, Jane Apperley, Dong-Wook Kim, Eduardo O. Bullorsky, Michele Baccarani, Gail J. Roboz, Sergio Amadori, Carmino A. de Souza, Jeffrey H. Lipton, Andreas Hochhaus, Dominik Heim, Richard A. Larson, Susan Branford, Martin C. Muller, Prasheen Agarwal, Ashwin Gollerkeri, Moshe Talpaz
Journal: Blood
Blood (2007) 109 (10): 4143–4150.
https://doi.org/10.1182/blood-2006-09-046839
Published: 2007
Journal Articles

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

Clinical Trials & Observations
Jorge Cortes, Philippe Rousselot, Dong-Wook Kim, Ellen Ritchie, Nelson Hamerschlak, Steven Coutre, Andreas Hochhaus, Francois Guilhot, Giuseppe Saglio, Jane Apperley, Oliver Ottmann, Neil Shah, Philipp Erben, Susan Branford, Prasheen Agarwal, Ashwin Gollerkeri, Michele Baccarani
Journal: Blood
Blood (2006) 109 (8): 3207–3213.
https://doi.org/10.1182/blood-2006-09-046888
Published: 2006
Journal Articles

Sustained Molecular Responses to Dasatanib (SPRYCEL®) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience.

Joerg Chromik, MD, Heike Pfeifer, MD, Lydia Wunderle, MD, Nadine Schoch, Barbara Wassmann, MD, Patrick Brueck, MD, Ashwin Gollerkeri, MD, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD
Journal: Blood
Blood (2006) 108 (11): 285.
https://doi.org/10.1182/blood.V108.11.285.285
Published: 2006